335 related articles for article (PubMed ID: 21300721)
21. MICE models: superior to the HERG model in predicting Torsade de Pointes.
Kramer J; Obejero-Paz CA; Myatt G; Kuryshev YA; Bruening-Wright A; Verducci JS; Brown AM
Sci Rep; 2013; 3():2100. PubMed ID: 23812503
[TBL] [Abstract][Full Text] [Related]
22. Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends.
Hoffmann P; Warner B
J Pharmacol Toxicol Methods; 2006; 53(2):87-105. PubMed ID: 16289936
[TBL] [Abstract][Full Text] [Related]
23. QT interval prolongation and cardiac risk assessment for novel drugs.
Picard S; Lacroix P
Curr Opin Investig Drugs; 2003 Mar; 4(3):303-8. PubMed ID: 12735231
[TBL] [Abstract][Full Text] [Related]
24. A step towards characterisation of electrophysiological profile of torsadogenic drugs.
Champeroux P; Ouillé A; Martel E; Fowler JS; Maurin A; Richard S; Le Guennec JY
J Pharmacol Toxicol Methods; 2011; 63(3):269-78. PubMed ID: 21224008
[TBL] [Abstract][Full Text] [Related]
25. Role of a KCNH2 polymorphism (R1047 L) in dofetilide-induced Torsades de Pointes.
Sun Z; Milos PM; Thompson JF; Lloyd DB; Mank-Seymour A; Richmond J; Cordes JS; Zhou J
J Mol Cell Cardiol; 2004 Nov; 37(5):1031-9. PubMed ID: 15522280
[TBL] [Abstract][Full Text] [Related]
26. Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.
Wu L; Rajamani S; Li H; January CT; Shryock JC; Belardinelli L
Am J Physiol Heart Circ Physiol; 2009 Sep; 297(3):H1048-57. PubMed ID: 19592609
[TBL] [Abstract][Full Text] [Related]
27. Drug block of I(kr): model systems and relevance to human arrhythmias.
Yang T; Snyders D; Roden DM
J Cardiovasc Pharmacol; 2001 Nov; 38(5):737-44. PubMed ID: 11602820
[TBL] [Abstract][Full Text] [Related]
28. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro.
Fanoe S; Jensen GB; Sjøgren P; Korsgaard MP; Grunnet M
Br J Clin Pharmacol; 2009 Feb; 67(2):172-9. PubMed ID: 19159406
[TBL] [Abstract][Full Text] [Related]
29. A history of the role of the hERG channel in cardiac risk assessment.
Rampe D; Brown AM
J Pharmacol Toxicol Methods; 2013; 68(1):13-22. PubMed ID: 23538024
[TBL] [Abstract][Full Text] [Related]
30. Efavirenz Inhibits the Human Ether-A-Go-Go Related Current (hERG) and Induces QT Interval Prolongation in CYP2B6*6*6 Allele Carriers.
Abdelhady AM; Shugg T; Thong N; Lu JB; Kreutz Y; Jaynes HA; Robarge JD; Tisdale JE; Desta Z; Overholser BR
J Cardiovasc Electrophysiol; 2016 Oct; 27(10):1206-1213. PubMed ID: 27333947
[TBL] [Abstract][Full Text] [Related]
31. Dehydroevodiamine and hortiamine, alkaloids from the traditional Chinese herbal drug Evodia rutaecarpa, are I
Baburin I; Varkevisser R; Schramm A; Saxena P; Beyl S; Szkokan P; Linder T; Stary-Weinzinger A; van der Heyden MAG; Houtman M; Takanari H; Jonsson M; Beekman JHD; Hamburger M; Vos MA; Hering S
Pharmacol Res; 2018 May; 131():150-163. PubMed ID: 29477480
[TBL] [Abstract][Full Text] [Related]
32. Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic.
Kang J; Compton DR; Vaz RJ; Rampe D
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1133-7. PubMed ID: 27530870
[TBL] [Abstract][Full Text] [Related]
33. Molecular interaction of droperidol with human ether-a-go-go-related gene channels: prolongation of action potential duration without inducing early afterdepolarization.
Schwoerer AP; Blütner C; Brandt S; Binder S; Siebrands CC; Ehmke H; Friederich P
Anesthesiology; 2007 May; 106(5):967-76. PubMed ID: 17457128
[TBL] [Abstract][Full Text] [Related]
34. The hERG potassium channel and hERG screening for drug-induced torsades de pointes.
Hancox JC; McPate MJ; El Harchi A; Zhang YH
Pharmacol Ther; 2008 Aug; 119(2):118-32. PubMed ID: 18616963
[TBL] [Abstract][Full Text] [Related]
35. Modulation of the heart's electrical properties by the anticonvulsant drug retigabine.
Rubi L; Kovar M; Zebedin-Brandl E; Koenig X; Dominguez-Rodriguez M; Todt H; Kubista H; Boehm S; Hilber K
Toxicol Appl Pharmacol; 2017 Aug; 329():309-317. PubMed ID: 28641963
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.
Beattie KA; Luscombe C; Williams G; Munoz-Muriedas J; Gavaghan DJ; Cui Y; Mirams GR
J Pharmacol Toxicol Methods; 2013; 68(1):88-96. PubMed ID: 23624022
[TBL] [Abstract][Full Text] [Related]
37. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation.
Guo L; Guthrie H
J Pharmacol Toxicol Methods; 2005; 52(1):123-35. PubMed ID: 15936217
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation.
Baczko I; Liknes D; Yang W; Hamming KC; Searle G; Jaeger K; Husti Z; Juhasz V; Klausz G; Pap R; Saghy L; Varro A; Dolinsky V; Wang S; Rauniyar V; Hall D; Dyck JR; Light PE
Br J Pharmacol; 2014 Jan; 171(1):92-106. PubMed ID: 24102184
[TBL] [Abstract][Full Text] [Related]
39. Anti-addiction drug ibogaine inhibits voltage-gated ionic currents: a study to assess the drug's cardiac ion channel profile.
Koenig X; Kovar M; Rubi L; Mike AK; Lukacs P; Gawali VS; Todt H; Hilber K; Sandtner W
Toxicol Appl Pharmacol; 2013 Dec; 273(2):259-68. PubMed ID: 23707769
[TBL] [Abstract][Full Text] [Related]
40. Electrophysiological profile of propiverine--relationship to cardiac risk.
Christ T; Wettwer E; Wuest M; Braeter M; Donath F; Champeroux P; Richard S; Ravens U
Naunyn Schmiedebergs Arch Pharmacol; 2008 Feb; 376(6):431-40. PubMed ID: 18092154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
